Georgetown investigator presents final PAPILLON trial results showing long-term survival in a subset of lung cancer
In the PAPILLON study, first-line amivantamab-chemotherapy demonstrates the longest overall survival reported for EGFR exon 20 insertion-positive advanced NSCLC
Andor goes full 'Papillon' in episode 10 'One Way Out'
